BEDFORD, Mass., Oct. 31, 2014 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX) announced today that the Centers for Medicare and
Medicaid Services (CMS) has released reimbursement rates for
screening and diagnostic 3D mammography. The action establishes
national average payment rates for the Category I Current
Procedural Terminology (CPT) code for 3D screening mammography and
creates a new add-on Healthcare Common Procedure Coding System
(HCPCS) code for 3D diagnostic mammography.
The Medicare payment rates will go into effect January 1, 2015 and will allow providers in the
U.S. to file reimbursement claims specific to screening and
diagnostic 3D mammography. The CMS Medicare Physician Fee Schedule
Final Rule issued today not only sets reimbursement rates for 3D
mammography, but also creates a pathway for private insurers to
explore broader coverage and payment options. The rates are as
follows:
- 3D screening mammography CPT code, 77063, assigned a payment
rate of approximately $57. This is an
add-on to the existing 2D mammography screening code, G0202, with
an assigned payment rate of approximately $135.
- 3D diagnostic mammography HCPCS code, G0279, assigned a payment
rate of approximately $57 for either
unilateral or bilateral images.
- This is an add-on to the existing 2D mammography unilateral
diagnostic code, G0206, with an assigned payment rate of
approximately $130.
- This is an add-on to the existing 2D mammography bilateral
diagnostic code, G0204, with an assigned payment rate of
approximately $165.
"The availability of reimbursement for 3D mammography is yet
another validation of the importance of this game-changing
technology in the screening and detection of breast cancer," said
Peter J. Valenti III, Division
President, Breast and Skeletal Health Solutions. "With the
extensive body of published studies, including the landmark
JAMA study, Hologic continues to lead the way in introducing
superior 3D mammography worldwide."
"Hologic's 3D mammography is currently the only FDA approved
system clinically proven to improve upon the accuracy of
traditional mammography by significantly increasing the detection
of invasive cancers, the cancers doctors worry about, while
simultaneously reducing unnecessary callbacks," Mr. Valenti noted.
"As a result, we are seeing increasing demand from physicians and
patients seeking the best option for screening and detection.
Ultimately, we believe this reimbursement will benefit women and
healthcare systems throughout the U.S. and we hope that the new
Medicare payment rates will allow more women access to this
potentially life-saving exam."
About Hologic's Genius 3D Mammography:
Hologic's Genius 3D mammography is the only 3D exam approved by
the FDA as clinically superior to traditional mammography. Genius
3D mammography detects significantly more invasive cancers and
reduces unnecessary call backs when compared to traditional
mammography. In a recent study published in the prestigious
Journal of the American Medical Association (JAMA),
researchers reported that Hologic's 3D technology detects 41% more
invasive breast cancers while significantly reducing
anxiety-provoking callbacks due to false alarms.1
Hologic's 3D mammography technology was approved for breast
cancer screening and diagnosis in the U.S. in February 2011 and has been available in countries
recognizing the CE mark since 2008. With over 2,000 systems
installed worldwide, Hologic's 3D mammography technology is in use
in all 50 states and over 50 countries. Over 8 million women in the
U.S. have already had a Hologic Genius 3D mammography exam. Genius
3D mammography is only available on the Hologic Selenia Dimensions
system. For more information, visit
www.Genius3DMammography.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, Dimensions, Genius 3D mammography, Selenia, and
associated logos are trademarks and/or registered trademarks of
Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about
Hologic's 3D mammography technology. There can be no assurance this
product will achieve the benefits described herein and that such
benefits will be replicated in any particular manner with respect
to an individual patient as the actual effect of the use of the
product can only be determined on a case-by-case basis depending on
the particular circumstances and patient in question. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts:
|
|
|
|
Investors
|
Media
|
Deborah R.
Gordon
|
Jim Culley
|
Vice President,
Investor Relations and
|
Senior Director,
Corporate Communications
|
Corporate
Communications
|
|
(781)
999-7716
|
(302)
528-1312
|
deborah.gordon@hologic.com
|
jim.culley@hologic.com
|
|
|
|
Marianne
McMorrow
|
|
Manager, Corporate
Communications
|
|
(781)
999-7723
|
|
marianne.mcmorrow@hologic.com
|
___________________________
1
Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM,
Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Barke LD,
Greer LN, Miller DP, Conant EF. Breast cancer screening using
tomosynthesis in combination with digital mammography. JAMA.
2014 Jun 25;311(24):2499-507. doi: 10.1001/jama.2014.6095.
SOURCE Hologic, Inc.